HealthcareServices

Revenue of the Neuropathic Pain Market Predicted to Achieve $8.47 Billion by 2030, Driven by 8.1% CAGR

February 27, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the neuropathic pain market from 2026–2035 with trusted insights from The Business Research Company

What was the valuation of the Neuropathic Pain Market in 2026, and what figure is it projected to hit by 2030?_x000D_

The neuropathic pain market has exhibited strong growth over recent years. It is forecast to grow from $5.78 billion in 2025 to $6.2 billion in 2026, achieving a compound annual growth rate (CAGR) of 7.3%. The expansion observed in the historical period can be attributed to an increasing prevalence of diabetes, the early adoption of antidepressants and anticonvulsants, enhanced awareness of neuropathic pain conditions, the creation of opioid-based treatments, and the initial utilization of imaging for diagnosis._x000D_

_x000D_

The market for neuropathic pain is projected to experience substantial growth over the coming years, anticipated to reach $8.48 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 8.1%. This expansion during the forecast period can be attributed to a growing preference for non-opioid treatments, the increasing need for individualized pain management, the wider adoption of complementary therapies, greater investment in diagnostic breakthroughs, and the creation of sophisticated multimodal treatment approaches. Prominent trends expected during this period involve a surge in multimodal therapy uptake, a heightened call for non-opioid pain relief, increased integration of physical and psychological therapies, advancements in early diagnosis via imaging methods, and an intensified focus on managing diabetic neuropathy._x000D_

_x000D_

#Access Your Free Sample Report for In-Depth Market Insights:#_x000D_

https://www.thebusinessresearchcompany.com/sample.aspx?id=12922&type=smp_x000D_

_x000D_

Which Drivers Are Affecting Market Participation In The Neuropathic Pain Market?_x000D_

The increasing occurrence of chronic pain is anticipated to fuel the expansion of the neuropathic pain market moving ahead. Chronic pain, characterized as ongoing discomfort persisting for at least three months, affects a considerable segment of the population and profoundly impacts their quality of life. This rise in chronic pain instances stems from factors including aging demographics, nerve injuries, and long-term health conditions such as diabetes. Therapies for neuropathic pain contribute to public health by addressing nerve dysfunction, alleviating symptoms, and enhancing patients’ daily activities. As an illustration, data released in November 2024 by the Centers for Disease Control and Prevention (CDC), a US-based national health protection agency, indicated that in 2023, adult populations experienced a 24.3% prevalence of chronic pain and an 8.5% prevalence of high-impact chronic pain, which translates to 34.9% among those with chronic pain, with women, American Indian and Alaska Native adults, and individuals aged 65 years and older exhibiting particularly elevated rates. Consequently, the growing prevalence of chronic pain is stimulating the neuropathic pain market._x000D_

_x000D_

What Segment Categories Are Covered In The Neuropathic Pain Market?_x000D_

The neuropathic pain market covered in this report is segmented –_x000D_

_x000D_

1) By Treatment: Medications, Multimodal Therapy_x000D_

2) By Diagnosis: Imaging, Blood Tests And Physical Examination_x000D_

3) By Indication: Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy, Other Indications_x000D_

4) By End User: Hospitals, Clinics, Home Healthcare, Ambulatory Surgical Centers, Other End Users_x000D_

_x000D_

Subsegments:_x000D_

1) By Medications: Anticonvulsants, Antidepressants, Opioids, Topical Treatments, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)_x000D_

2) By Multimodal Therapy: Combination Of Medications, Physical Therapy, Psychological Therapy, Lifestyle Modifications, Complementary Therapies_x000D_

_x000D_

How Are New Market Trends Shaping The Landscape Of The Neuropathic Pain Market?_x000D_

Companies operating within the neuropathic pain market are increasingly integrating artificial intelligence technologies for improved diagnosis, personalized treatment plans, real-time patient monitoring, drug discovery, and data-driven insights. These efforts are aimed at enhancing patient outcomes and refining pain management strategies. For instance, in March 2023, Nevro Corp., a medical device company based in the US, introduced its Senza HFX iQ spinal cord stimulation (SCS) system. This innovative technology harnesses artificial intelligence (AI) to customize pain relief for individual patients. The system, which comprises the HFX iQ Implantable Pulse Generator (IPG), HFX Trial Stimulator, Charger, and HFX App, is designed to address non-surgical back pain and painful diabetic neuropathy by adapting to patient responses and feedback. It utilizes a distinct algorithm derived from extensive patient data, enabling patients to modify their pain relief program via a smartphone application. The system’s digital platform supports data collection and potential updates. The objective of this technology is to elevate pain relief through consistency and personalization, representing a notable advancement in SCS therapy._x000D_

_x000D_

Which Leading Companies Dominate The Neuropathic Pain Market Share?_x000D_

Major companies operating in the neuropathic pain market are Pfizer Inc., Johnson & Johnson Private Limited, Sanofi S.A., Bristol-Myers Squibb Company, Abbott Laboratories, GlaxoSmithKline Plc, Medtronic Inc., Eli Lilly and Company, Teva Pharmaceutical Industries Ltd, Boston Scientific Corporation, Sun Pharmaceutical Industries Ltd., Mallinckrodt Pharmaceuticals, Grünenthal GmbH, Lupin Ltd., Nevro Corp., InvaGen Pharmaceuticals Inc, Centaur Pharmaceuticals Pvt Ltd., Stimwave LLC, Novartis AG, Astellas Pharma Inc., Vertex Pharmaceuticals Incorporated, Assertio Therapeutics Inc, NeuroMetrix Inc, OMRON Healthcare Co Ltd_x000D_

_x000D_

#Access The Complete Report For Deeper Market Insights:#_x000D_

https://www.thebusinessresearchcompany.com/report/neuropathic-pain-global-market-report_x000D_

_x000D_

Which Region Is Anticipated To See The Fastest Growth In The Neuropathic Pain Market?_x000D_

North America was the largest region in the neuropathic pain market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the neuropathic pain market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa._x000D_

_x000D_

#Request Your Customized Neuropathic Pain Market Research Report for Competitive Advantage:#_x000D_

https://www.thebusinessresearchcompany.com/customise?id=12922&type=smp_x000D_

_x000D_

#Browse Through More Reports Similar to the Global Neuropathic Pain Market 2026, By The Business Research Company#_x000D_

_x000D_

Keloids Treatment Market Report 2026_x000D_

https://www.thebusinessresearchcompany.com/report/keloids-treatment-global-market-report_x000D_

_x000D_

Actinic Keratosis Treatment Market Report 2026_x000D_

https://www.thebusinessresearchcompany.com/report/actinic-keratosis-treatment-global-market-report_x000D_

_x000D_